Contribute Try STAT+ Today

Gilead Sciences (GILD) is preparing to lay off approximately 20% of its sales force now that two of its older drugs have lost patent protection and face competition from lower-priced generics, STAT has learned.

The decision to cut 150 long-tenured sales people — confirmed by a Gilead spokesperson — is being explained internally as an unfortunate but necessary cost-cutting move. But to some Gilead employees, the firings are another worrisome sign that the company’s executive team, led by recently appointed CEO Daniel O’Day, is struggling to find ways to grow revenue and earnings.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.